Genmab initiates combination study of HuMax-EGFr with chemo-radiation
The open label study consists of an initial dose-escalation part and a subsequent parallel group design. In the dose-escalation part of the study, three dose levels of HuMax-EGFr will be tested in combination with conventional fractionated radiotherapy and cisplatin. Patients in the first treatment group will receive one initial dose of 8 mg/kg of HuMax-EGFr followed by seven weekly maintenance doses of 4 mg/kg. The safety of this dose level will then be evaluated before dosing is continued at the next level. The planned dosing for the two other dose groups is an initial dose of 12 or 16 mg/kg followed by seven weekly maintenance doses of 8 or 12 mg/kg, respectively, but can be adjusted according to safety data from the first treatment group.
In the following parallel group design part of the study, HuMax-EGFr will be tested in combination with cisplatin and three different regimes of accelerated radiotherapy. All patients in the study will be evaluated four weeks after administration of the last dose of HuMax-EGFr and will be followed for at least three years.
The objective of the study is to investigate the safety and efficacy of HuMax-EGFr in combination with chemo-radiation as first line treatment of patients with advanced SCCHN. The primary endpoint of the study is safety and patients will also be evaluated for efficacy.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.